Logotipo do repositório
 

Publicação:
Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination

Página do item simplificado
dc.contributor.authorFurlan Pagliotto, Aline Daniele
dc.contributor.authorCaleffi-Ferracioli, Katiany Rizzieri
dc.contributor.authorLopes, Mariana Aparecida
dc.contributor.authorBaldin, Vanessa Pietrowski
dc.contributor.authorFujimura Leite, Clarice Queico [UNESP]
dc.contributor.authorPavan, Fernando Rogerio [UNESP]
dc.contributor.authorLima Scodro, Regiane Bertin de
dc.contributor.authorDias Siqueira, Vera Lucia
dc.contributor.authorCardoso, Rosilene Fressatti
dc.contributor.institutionUniversidade Estadual de Maringá (UEM)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-11-26T17:13:49Z
dc.date.available2018-11-26T17:13:49Z
dc.date.issued2016-12-01
dc.description.abstractWe report the in vitro drugs interaction by the resazurin drugs combination micro-titer assay (REDCA) of amoxicillin (AMO)/clavulanate (CLAV) with isoniazid (INH), ethambutol (EMB), and rifampicin (RIF) against susceptible and resistant Mycobacterium tuberculosis isolates. The addition of AMO/CLAV to classical antituberculosis drugs should be explored as a promising alternative for the treatment of resistant tuberculosis (TB). Copyright (C) 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.en
dc.description.affiliationUniv Estadual Maringa, Postgraduate Program Hlth Sci, BR-87020900 Maringa, Parana, Brazil
dc.description.affiliationUniv Estadual Maringa, Dept Clin Anal & Biomedicine, BR-87020900 Maringa, Parana, Brazil
dc.description.affiliationUniv Estadual Paulista, Sch Pharmaceut Sci, Dept Biol Sci, BR-14800901 Sao Paulo, Araraquara, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, Sch Pharmaceut Sci, Dept Biol Sci, BR-14800901 Sao Paulo, Araraquara, Brazil
dc.format.extent980-983
dc.identifierhttp://dx.doi.org/10.1016/j.jmii.2015.08.025
dc.identifier.citationJournal Of Microbiology Immunology And Infection. Taipei: Elsevier Taiwan, v. 49, n. 6, p. 980-983, 2016.
dc.identifier.doi10.1016/j.jmii.2015.08.025
dc.identifier.fileWOS000389596000022.pdf
dc.identifier.issn1684-1182
dc.identifier.urihttp://hdl.handle.net/11449/162237
dc.identifier.wosWOS:000389596000022
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofJournal Of Microbiology Immunology And Infection
dc.relation.ispartofsjr0,789
dc.rights.accessRightsAcesso abertopt
dc.sourceWeb of Science
dc.subjectamoxicillin/clavulanate
dc.subjectcheckerboard
dc.subjectMycobacterium tuberculosis
dc.subjectsynergism
dc.subjecttuberculosis
dc.titleAnti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combinationen
dc.typeArtigopt
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dcterms.rightsHolderElsevier B.V.
dspace.entity.typePublication
relation.isDepartmentOfPublication5004bcab-94af-4939-b980-091ae9d0a19e
relation.isDepartmentOfPublication.latestForDiscovery5004bcab-94af-4939-b980-091ae9d0a19e
unesp.departmentCiências Biológicas - FCFpt

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000389596000022.pdf
Tamanho:
227.31 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar

Coleções

Araraquara - FCF - Faculdade de Ciências Farmacêuticas